Exenatide Effects on Cardiometabolic Risk and Weight in Adolescents with Morbid Obesity and Type 2 Diabetes Mellitus: Two Case Reports.

Censani, Marisa; Chin, Vivian L; Fennoy, Ilene

dc.contributor.author	Censani, Marisa
dc.contributor.author	Chin, Vivian L
dc.contributor.author	Fennoy, Ilene
dc.date.accessioned	2023-05-12T17:07:45Z
dc.date.available	2023-05-12T17:07:45Z
dc.date.issued	2015-05-06
dc.identifier.citation	Censani M, Chin VL, Fennoy I. Exenatide Effects on Cardiometabolic Risk and Weight in Adolescents with Morbid Obesity and Type 2 Diabetes Mellitus: Two Case Reports. J Obes Weight Loss Medicat. 2015;1(1):004. doi: 10.23937/2572-4010.1510004. Epub 2015 May 6. PMID: 27182560; PMCID: PMC4864000.	en_US
dc.identifier.pmid	27182560
dc.identifier.uri	http://hdl.handle.net/20.500.12648/8701
dc.description.abstract	Glucagon-like peptide-1 (GLP-1) receptor agonists improve glycemic control and cardiometabolic risk factors in adults with type 2 diabetes mellitus, but pediatric data is sparse.
dc.description.abstract	This is the first report to describe the effects of GLP-1 receptor agonist Exenatide on metabolic risk and weight in adolescents with morbid obesity (BMI>35kg/m) and type 2 diabetes in the first 6 months after treatment initiation. Two patients with morbid obesity who failed conventional therapy with insulin glargine and Metformin were treated with the addition of Exenatide. Metabolic parameters were obtained at 3 and 6 months post intervention.
dc.description.abstract	Improvements in cardiometabolic risk factors, such as fasting glucose and triglyceride levels, as well as HbA1c, were reached at 6 months compared to baseline.
dc.description.abstract	Our cases highlight the therapeutic potential of exenatide for adolescent patients with morbid obesity and type 2 diabetes.
dc.language.iso	en	en_US
dc.relation.url	https://clinmedjournals.org/articles/jowm/jowm-1-004.php?jid=jowm	en_US
dc.rights	Attribution-NonCommercial-NoDerivatives 4.0 International	*
dc.rights.uri	http://creativecommons.org/licenses/by-nc-nd/4.0/	*
dc.subject	Adolescents	en_US
dc.subject	Exenatide	en_US
dc.subject	Obesity	en_US
dc.subject	Type 2 diabetes	en_US
dc.title	Exenatide Effects on Cardiometabolic Risk and Weight in Adolescents with Morbid Obesity and Type 2 Diabetes Mellitus: Two Case Reports.	en_US
dc.type	Article/Review	en_US
dc.source.journaltitle	Journal of obesity and weight-loss medication	en_US
dc.source.volume	1
dc.source.issue	1
dc.source.country	United States
dc.source.country	United States
dc.description.version	VoR	en_US
refterms.dateFOA	2023-05-12T17:07:46Z
html.description.abstract	Glucagon-like peptide-1 (GLP-1) receptor agonists improve glycemic control and cardiometabolic risk factors in adults with type 2 diabetes mellitus, but pediatric data is sparse.
html.description.abstract	This is the first report to describe the effects of GLP-1 receptor agonist Exenatide on metabolic risk and weight in adolescents with morbid obesity (BMI>35kg/m) and type 2 diabetes in the first 6 months after treatment initiation. Two patients with morbid obesity who failed conventional therapy with insulin glargine and Metformin were treated with the addition of Exenatide. Metabolic parameters were obtained at 3 and 6 months post intervention.
html.description.abstract	Improvements in cardiometabolic risk factors, such as fasting glucose and triglyceride levels, as well as HbA1c, were reached at 6 months compared to baseline.
html.description.abstract	Our cases highlight the therapeutic potential of exenatide for adolescent patients with morbid obesity and type 2 diabetes.
dc.description.institution	SUNY Downstate	en_US
dc.description.department	Pediatrics, Division of Pediatric Endocrinology	en_US
dc.description.degreelevel	N/A	en_US
dc.identifier.journal	Journal of obesity and weight-loss medication